 ATLANTA, GA, Oct. 26, 2020 GLOBE NEWSWIRE -- via NewMediaWire GeoVax Labs, Inc. NasdaqCM: GOVX, GOVXW GeoVax or the Company, a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement the License Agreement with the National Institute of Allergy and Infectious Diseases NIAID, part of the National Institutes of Health NIH, in support of GeoVaxs development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Patent License Agreement to GeoVax includes access to NIAIDs patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue. 